Akash Tewari
Stock Analyst at Jefferies
(2.39)
# 2,524
Out of 5,116 analysts
61
Total ratings
39.13%
Success rate
3.82%
Average return
Main Sectors:
Stocks Rated by Akash Tewari
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Buy | $28 → $35 | $34.60 | +1.16% | 2 | Nov 3, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $83 → $96 | $82.67 | +16.12% | 2 | Sep 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $813 → $831 | $741.45 | +12.08% | 5 | Aug 27, 2025 | |
| CBIO Crescent Biopharma | Initiates: Buy | $26 | $9.59 | +171.12% | 1 | Aug 25, 2025 | |
| ARVN Arvinas | Downgrades: Hold | $52 → $10 | $13.38 | -25.26% | 3 | May 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $70 → $68 | $55.05 | +23.52% | 4 | Apr 23, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Outperform | $95 | $56.54 | +68.02% | 2 | Nov 15, 2024 | |
| BNTX BioNTech SE | Upgrades: Buy | $96 → $150 | $113.75 | +31.87% | 3 | Sep 17, 2024 | |
| RLAY Relay Therapeutics | Upgrades: Buy | $11 → $16 | $7.66 | +108.88% | 3 | Sep 10, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $177 → $189 | $136.06 | +38.91% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $22.58 | +254.30% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $994 → $1,015 | $1,037.15 | -2.14% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $50 | $33.89 | +47.54% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $75 | $65.51 | +14.49% | 4 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $31.98 | -3.06% | 1 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $38 → $39 | $26.44 | +47.50% | 2 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $49 → $18 | $12.90 | +39.53% | 2 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $497 → $513 | $840.50 | -38.96% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $110.27 | +13.36% | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7.7 → $11 | $22.53 | -51.18% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $1.79 | +849.72% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $63.19 | +18.69% | 2 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $151 | $489.31 | -69.14% | 1 | Oct 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $41.36 | -32.30% | 3 | Oct 7, 2021 |
Terns Pharmaceuticals
Nov 3, 2025
Maintains: Buy
Price Target: $28 → $35
Current: $34.60
Upside: +1.16%
Ionis Pharmaceuticals
Sep 2, 2025
Maintains: Buy
Price Target: $83 → $96
Current: $82.67
Upside: +16.12%
Regeneron Pharmaceuticals
Aug 27, 2025
Maintains: Buy
Price Target: $813 → $831
Current: $741.45
Upside: +12.08%
Crescent Biopharma
Aug 25, 2025
Initiates: Buy
Price Target: $26
Current: $9.59
Upside: +171.12%
Arvinas
May 2, 2025
Downgrades: Hold
Price Target: $52 → $10
Current: $13.38
Upside: -25.26%
Bristol-Myers Squibb Company
Apr 23, 2025
Maintains: Buy
Price Target: $70 → $68
Current: $55.05
Upside: +23.52%
BioMarin Pharmaceutical
Nov 15, 2024
Initiates: Outperform
Price Target: $95
Current: $56.54
Upside: +68.02%
BioNTech SE
Sep 17, 2024
Upgrades: Buy
Price Target: $96 → $150
Current: $113.75
Upside: +31.87%
Relay Therapeutics
Sep 10, 2024
Upgrades: Buy
Price Target: $11 → $16
Current: $7.66
Upside: +108.88%
Neurocrine Biosciences
Aug 19, 2024
Maintains: Buy
Price Target: $177 → $189
Current: $136.06
Upside: +38.91%
Jul 31, 2024
Maintains: Buy
Price Target: $80
Current: $22.58
Upside: +254.30%
Jun 24, 2024
Maintains: Buy
Price Target: $994 → $1,015
Current: $1,037.15
Upside: -2.14%
Apr 9, 2024
Maintains: Buy
Price Target: $42 → $50
Current: $33.89
Upside: +47.54%
Mar 6, 2024
Maintains: Buy
Price Target: $37 → $75
Current: $65.51
Upside: +14.49%
Dec 11, 2023
Initiates: Buy
Price Target: $31
Current: $31.98
Upside: -3.06%
Oct 16, 2023
Upgrades: Buy
Price Target: $38 → $39
Current: $26.44
Upside: +47.50%
Aug 8, 2023
Downgrades: Hold
Price Target: $49 → $18
Current: $12.90
Upside: +39.53%
Jul 17, 2023
Maintains: Buy
Price Target: $497 → $513
Current: $840.50
Upside: -38.96%
Mar 6, 2023
Initiates: Buy
Price Target: $125
Current: $110.27
Upside: +13.36%
Dec 20, 2022
Upgrades: Buy
Price Target: $7.7 → $11
Current: $22.53
Upside: -51.18%
Dec 12, 2022
Initiates: Buy
Price Target: $17
Current: $1.79
Upside: +849.72%
Oct 7, 2021
Initiates: Buy
Price Target: $75
Current: $63.19
Upside: +18.69%
Oct 7, 2021
Initiates: Buy
Price Target: $151
Current: $489.31
Upside: -69.14%
Oct 7, 2021
Initiates: Buy
Price Target: $28
Current: $41.36
Upside: -32.30%